BioMarin Pharmaceutical Inc. (BMRN) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Good morning, and welcome once again to TD Cowen's 46th Annual Healthcare Conference. I'm Phil Nadeau, one of the biotech analysts here at Cowen, and it's my pleasure to do a fireside chat with ...

BioMarin Pharmaceutical Details Strategy Refresh, Voxzogo Competition and 40% Margin Goal at TD Cowen Confab

BioMarin Pharmaceutical (NASDAQ:BMRN) executives used a fireside chat at TD Cowen’s 46th Annual Healthcare Conference to ...

BioMarin signals $3.325B–$3.425B 2026 revenue target as acquisitions and pipeline drive growth

Q4 2025 Management View CEO Alexander Hardy announced that total revenues for 2025 grew by 13% to $3.22 billion, highlighting a 9% increase in enzyme therapies revenue and a 26% rise in Voxzogo ...
The Business Journals

After shakeup under new CEO, drugmaker BioMarin turns its cash on a big deal

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A new leader is reshaping the ...
Morningstar

BioMarin Appoints Arpit Davé Chief Digital and Information Officer

Mr. Davé Brings more than 20 Years of Experience in Creating Enterprise Value through Digital Transformation, Information Technology and Artificial Intelligence across the Biopharmaceutical Industry ...
Insider Monkey

BioMarin (BMRN) Jumps 17.7% on $5-Billion Merger with Amicus

We recently published 10 Firms in the Limelight. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best performers on Friday. BioMarin Pharmaceutical extended its winning streak to a third ...